Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has shared an update.
Hikma Pharmaceuticals has continued to execute its $250 million share buyback programme, repurchasing 747,632 ordinary shares on the London Stock Exchange between 9 and 13 March 2026, at volume-weighted average prices ranging from about 1,198p to 1,222p. These repurchased shares will be cancelled, reducing the free float and potentially enhancing earnings per share for remaining investors.
Since the buyback’s launch on 26 February 2026, Hikma has acquired 2,326,376 shares for a total of £29.0 million, while retaining 12,833,233 shares in treasury and leaving 219,560,077 ordinary shares in issue with the same number of voting rights. The ongoing programme underscores the group’s capital-return strategy and balance-sheet confidence at a time when many pharmaceutical peers are also using buybacks to support shareholder value and optimise capital allocation.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals group listed in London and on Nasdaq Dubai. The company focuses on developing, manufacturing and marketing branded and non-branded generics, injectables and specialty medicines for global markets, with a strong presence in the Middle East, North Africa, Europe and the U.S.
Average Trading Volume: 1,141,046
Technical Sentiment Signal: Sell
Current Market Cap: £2.71B
For an in-depth examination of HIK stock, go to TipRanks’ Overview page.